NextFin
Portfolio
Explore
My Agents›
Dow Futures
- (-)
Nasdaq Futures
- (-)
S&P Futures
- (-)
Russell 2000 Futures
- (-)
Nikkei 225
- (-)
CBOE Volatility Index
- (-)
Gold Futures
- (-)
Crude Oil
- (-)
BTC
- (-)
ETH
- (-)
Dow Futures
- (-)
Nasdaq Futures
- (-)
S&P Futures
- (-)
Russell 2000 Futures
- (-)
Nikkei 225
- (-)
CBOE Volatility Index
- (-)
Gold Futures
- (-)
Crude Oil
- (-)
BTC
- (-)
ETH
- (-)
NextFin

Yingjiexin Medical Completes 200 Million Yuan Series B

AsianFinbadge
AsianFin2 days ago
Summarized by NextFin AI
  • Shanghai Yingjiexin Medical Technology completed a Series B financing round of 200 million yuan, led by a fund under CICC Capital with participation from multiple investors.
  • Existing shareholder GSR Ventures continued its investment, while Haoyue Capital served as the exclusive financial adviser for the transaction.
  • Proceeds will expand global production and delivery capacity, accelerate R&D and commercialization of next-generation self-administration devices.
  • The company focuses on high-precision drug delivery devices for biologics such as GLP-1 agonists and insulin, supporting overseas registration and market expansion.

NextFin News — Shanghai Yingjiexin Medical Technology has completed a Series B financing of 200 million yuan.

The round was led by a fund under CICC Capital, with participation from Zhuhai Science and Technology Industry Group, Keystone Capital, Qiming Venture Partners, Houxin Health Investment and Yingyue Fund. Existing shareholder GSR Ventures continued its investment, and Haoyue Capital served as exclusive financial adviser.

Proceeds will expand global production and delivery capacity, accelerate research and commercialization of next-generation self-administration devices, and support overseas product registration, market expansion and customer service systems. The company focuses on high-precision drug delivery devices for biologics such as GLP-1 agonists and insulin.

Explore more exclusive insights at nextfin.ai.

Insights

What does Yingjiexin Medical Company do?

What are GLP-1 agonists mainly used for?

How do self-administration devices work?

Is high-precision drug delivery growing?

Where is Yingjiexin Medical based?

Who led the Series B funding round?

How much funding was raised total?

Which investors joined the round?

Did GSR Ventures invest again?

Who advised on this financing deal?

How will Yingjiexin use the funds?

Will production capacity expand globally?

Are overseas registrations planned soon?

What devices are being developed now?

How will this boost global expansion?

What is the future insulin device trend?

What hurdles face overseas registration?

Is competition fierce in drug delivery?

Who are Yingjiexin's main competitors?

How does this compare to rival funding?

Search, ask or analyze anything...